Reuters logo
6 months ago
BRIEF-FDA grants Cellectis IND approval to proceed with development of UCART123
February 6, 2017 / 10:09 PM / 6 months ago

BRIEF-FDA grants Cellectis IND approval to proceed with development of UCART123

Feb 6 (Reuters) - Cellectis SA :

* FDA grants cellectis IND approval to proceed with the clinical development of UCART123, the first gene edited off-the-shelf car t-cell product candidate developed in the U.S.

* Intends to initiate phase 1 trials in first half of 2017 Source text for Eikon: Further company coverage: (Gdynia Newsroom:)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below